Drug Profile

JBZ 001

Alternative Names: JBZ-001

Latest Information Update: 27 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jabez Biosciences
Class Antineoplastics; Small molecules
Mechanism of Action Dihydroorotate dehydrogenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Haematological malignancies; Solid tumours
Preclinical Multiple myeloma

Most Recent Events

31 Jan 2025 Jabez Bioscience grants patent for JBZ 001 in cancer in Japan and Mexico, before January 2025
31 Jan 2025 Jabez Bioscience grants patent for "Methods and Compositions for Inhibition of Dihydroorotate Dehydrogenase" in China and Europe before January 2025
31 Jan 2025 Jabez Bioscience has patent pending for JBZ 001 in cancer in Canada, South Korea and Singapore, before January 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com